Skip to main content

Sacroiliac Joint Dysfunction

0
Pipeline Programs
4
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

PainTEQ
PainTEQFL - Tampa
1 program
Bone AllograftN/A2 trials
Active Trials
NCT07558278Not Yet Recruiting200Est. Jul 2029
NCT07547215Not Yet Recruiting100Est. Dec 2028
Spine BioPharma
Spine BioPharmaNY - New York
1 program
SImmetryN/A1 trial
Active Trials
NCT02074761Unknown250Est. Nov 2020
Nevro
NevroCA - Redwood City
1 program
Sacroiliac Joint transfixing and fusion systemN/A1 trial
Active Trials
NCT06909292Recruiting180Est. Jun 2027
SI-BONE
SI-BONESANTA CLARA, CA
1 program
Use of iFuse TORQPHASE_41 trial
Active Trials
NCT05870488Active Not Recruiting110Est. Nov 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
PainTEQBone Allograft
SI-BONEUse of iFuse TORQ
PainTEQBone Allograft
NevroSacroiliac Joint transfixing and fusion system
Spine BioPharmaSImmetry

Clinical Trials (5)

Total enrollment: 840 patients across 5 trials

NCT07558278PainTEQBone Allograft

An Open Label Randomized, Controlled, Multicenter, Prospective, Long Term Clinical Study Using the LINQ® System

Start: Jul 2026Est. completion: Jul 2029200 patients
Phase 4Not Yet Recruiting
NCT05870488SI-BONEUse of iFuse TORQ

iFuse TORQ for the Treatment of Sacroiliac Joint Dysfunction

Start: May 2023Est. completion: Nov 2027110 patients
Phase 4Active Not Recruiting
NCT07547215PainTEQBone Allograft

Post-Market Clinical Study Using TRAQ™ for Minimally Invasive Posterior Sacroiliac Joint Fusion

Start: May 2026Est. completion: Dec 2028100 patients
N/ANot Yet Recruiting
NCT06909292NevroSacroiliac Joint transfixing and fusion system

Sacroiliac (SI) Joint Transfixing and Fusion: Meaningful Long Term Outcomes With Nevro1

Start: Apr 2025Est. completion: Jun 2027180 patients
N/ARecruiting
NCT02074761Spine BioPharmaSImmetry

Evolusion Study Using the Zyga SImmetry Sacroiliac Joint Fusion System

Start: Jan 2015Est. completion: Nov 2020250 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 840 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.